A recent media story reported an investment of $1,200 that grew to $288,000 over 30 years, which is a 240-fold increase. Angel investment refers to the provision of capital to entrepreneurs to advance the quality of life, while also generating a return on the capital. Daktari Biotechnology Ltd is currently offering an opportunity to invest $200. This investment will be utilized to support the production of medicine and vaccines in Africa. The projected growth in value of the $200 investment is estimated to be approximately $1,500 within the first 5 years, and thereafter potentially increasing to about $20,000 over the following 20 years.
My name is Dr. Wilson Endege, and I am originally from Vihiga County in Kenya. Since relocating to the United States in 1992, I have pursued a career in molecular biology and drug development research, making significant contributions to the pharmaceutical sector. My experience includes positions at Harvard University, Chiron Diagnostics Inc., Millennium Pharmaceuticals Inc., and AstraZeneca Pharmaceuticals. Additionally, over the past 20 years, I have invested considerable resources in founding Daktari Biotechnology Company.
The medicine and vaccines sector in Kenya and Africa exhibits relatively limited development. The global gross domestic product (GDP) for medicines and vaccines is approximately $2 trillion, which accounts for approximately 1.7% of the total world GDP of $115 trillion. This $2 trillion serves a global population of roughly 8 billion people. Africa, with a population of 1.4 billion—representing 17% of the world's population —is served by approximately 5% of the $2 trillion medicine and vaccine GDP, equating to around $100 billion. These figures underscore the significant potential for capital investment in the medicines and vaccines sector.
Five scientists have collaborated with me in establishing Daktari Biotechnology Ltd. Three of them are Diaspora Kenyans: Dr. Patrick Shompole of Pullman, WA; Dr. Benson Edagwa of Omaha, NE; and Dr. Bernard Ayanga of Houston, TX.
We cordially invite Diaspora Kenyans, as well as Kenyans and others who are interested in becoming Founding Angel Investors, to join us in creating a company that expands the Kenyan and African market for medicines and vaccines, leveraging Kenya's and Africa's GDP growth.
Through 60,000 investments of $200 or KSh 25,000, we are inviting Diaspora Kenyans, Kenyans, and their friends to invest. Our aim is for the company to achieve $200 million in revenue and reach a valuation of $300 million by December 2030.
Fifty of the largest pharmaceutical companies have a market capitalization ranging from $15 billion to $580 billion, with a combined valuation of $4.7 trillion. Join us in developing Daktari Biotechnology Ltd into a company that achieves a market valuation of $1 billion (KSh 120 billion) within 10 years, or by 2035.
